Table 3.

Risk of neurotoxicity associated with the genetic variants of the vincristine pathway in the presence of clinical covariates.

Variable	Neurotoxicity 1/2			Neurotoxicity 3/4
	Sig. (p)	OR	95% CI	Sig. (p)	OR	95% CI
Age	0.06	3.9	0.9–16.1	0.2	2.9	0.6–15.1
Risk group	0.6	1.2	0.6–2.5	0.3	0.6	0.2–1.6
BSA	0.4	0.5	0.1–2.4	0.4	2.3	0.4–13.7
Treatment protocol	0.002	1.7	1.2–2.4	0.002	1.9	1.3–2.9
ABCB1 rs4728709	0.02	0.3	0.1–0.9
ACTG1 rs1135989				0.03	2.6	1.1–6.0
CAPG rs3770102				0.02	0.07	0.01–0.6

The risk (OR and 95% CI), of neurotoxicity grades 1/2 and 3/4 associated with the minor allele of indicated ABCB1, ACTG1 and CAPG polymorphisms in the presence of clinical covariates. The referent categories for these covariates were age ≥1 and <10, standard risk group and the most recent treatment protocol (00-01); BSA was a continuous variable.

Blank cells show that the p-value was not significant for the association between neurotoxicity and polymorphism.

BSA: Body surface area; OR: Odds ratio; Sig.: Significance.